Santana-Román Estefanía, Ortega-Robles Emmanuel, Arias-Carrión Oscar
Unidad de Trastornos del Movimiento y Sueño (TMS), Hospital General Dr. Manuel Gea González, Ciudad de México, 14080, México.
Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México, 04510, México.
Sci Rep. 2025 Jul 26;15(1):27284. doi: 10.1038/s41598-025-13558-3.
Parkinson's disease (PD) is a clinically heterogeneous neurodegenerative disorder whose trajectory is shaped by progressive motor impairment and cortical dysfunction. However, longitudinal studies integrating clinical scales with direct neurophysiological assessments remain scarce. In this 4.5-year cohort study, we conducted one of the longest clinical-electrophysiological follow-ups in PD to date, evaluating 22 patients across early and advanced stages using both Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores and transcranial magnetic stimulation (TMS). We demonstrate that the cortical silent period (CSP), a marker of GABAergic inhibition, progressively lengthens over time and is associated with motor decline, suggesting its potential as a dynamic biomarker of disease progression. Resting motor threshold (rMT) and motor asymmetry also deteriorated longitudinally, with changes most pronounced following the COVID-19 pandemic-suggesting that environmental stressors may accelerate PD pathophysiology. Unlike prior short-term studies, our findings reveal persistent cortical reorganization over several years, independent of sex, and underscore the clinical relevance of TMS-derived metrics in tracking disease progression. These findings suggest that CSP may serve as a non-invasive and scalable biomarker for monitoring Parkinson's disease progression and informing neurophysiological endpoints in future therapeutic studies.
帕金森病(PD)是一种临床异质性神经退行性疾病,其病程由进行性运动障碍和皮质功能障碍所决定。然而,将临床量表与直接神经生理学评估相结合的纵向研究仍然很少。在这项为期4.5年的队列研究中,我们进行了迄今为止帕金森病最长时间的临床-电生理随访之一,使用运动障碍协会统一帕金森病评定量表(MDS-UPDRS)评分和经颅磁刺激(TMS)对22例早期和晚期患者进行了评估。我们证明,作为γ-氨基丁酸能抑制标志物的皮质静息期(CSP)随时间逐渐延长,且与运动功能下降相关,这表明其有可能作为疾病进展的动态生物标志物。静息运动阈值(rMT)和运动不对称性也随时间恶化,在2019冠状病毒病大流行后变化最为明显,这表明环境应激源可能加速帕金森病的病理生理过程。与之前的短期研究不同,我们的研究结果揭示了数年持续的皮质重组,与性别无关,并强调了TMS衍生指标在追踪疾病进展中的临床相关性。这些发现表明,CSP可能作为一种无创且可扩展的生物标志物,用于监测帕金森病进展,并为未来治疗研究中的神经生理学终点提供信息。